9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery

Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery

Estimated reading time: < 1 min

Condition: Solid Organ Cancers

Estimated Enrollment: 36

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Number of participants with treatment-related adverse events as defined by CTCAE v4.03.,  The presence of GL-ONC1 within malignant tumors by examination of the resected surgical specimen.,  The maximum concentration (Cmax) of GL-ONC1 in blood after administration, Level of anti-vaccinia neutralizing antibodies in serum

Interventions: GL-ONC1,

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: March 2019

Completion Date: March 2021

Last  Posted Date: June 27, 2017

Location: UC San Diego Moores Cancer Center, La Jolla, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT02714374

Was this article helpful?
Dislike 0